2023-05-26 |
2023-05-25 |
K
Kauf
|
Vaddi Krishna
CEO
Geschäftsführender Verwaltungsratsmitglied
|
900
+0.1%
5,31
4.779
USD
|
900
+0.1%
|
5,31
|
4.779
USD
|
|
2023-05-26 |
2023-05-24 |
K
Kauf
|
Vaddi Krishna
CEO
Geschäftsführender Verwaltungsratsmitglied
|
1.000
+0.1%
5,01
5.011
USD
|
1.000
+0.1%
|
5,01
|
5.011
USD
|
|
2023-05-25 |
2023-05-24 |
K
Kauf
|
Lim Bryant David
Chief Legal Officer, Corp Sec.
Führungsperson
|
2.400
+inf%
5,39
12.936
USD
|
2.400
+inf%
|
5,39
|
12.936
USD
|
|
2023-05-25 |
2023-05-23 |
K
Kauf
|
Vaddi Krishna
CEO
Geschäftsführender Verwaltungsratsmitglied
|
11.856
+1.1%
5,63
66.749
USD
|
11.856
+1.1%
|
5,63
|
66.749
USD
|
|
2023-05-25 |
2023-05-23 |
GK
Geplanter Kauf
|
Chardonnet Laurent
Chief Financial Officer
Führungsperson
|
5.000
+13.5%
5,50
27.500
USD
|
5.000
+13.5%
|
5,50
|
27.500
USD
|
|
2023-05-24 |
2023-05-22 |
K
Kauf
|
ORBIMED ADVISORS LLC
Nicht geschäftsführender Verwaltungsratsmitglied
Large shareholder
|
869.565
+9.4%
5,75
4.999.999
USD
|
869.565
+9.4%
|
5,75
|
4.999.999
USD
|
|
2023-05-24 |
2023-05-22 |
K
Kauf
|
Bonita David P
Nicht geschäftsführender Verwaltungsratsmitglied
Large shareholder
|
869.565
+9.4%
5,75
4.999.999
USD
|
869.565
+9.4%
|
5,75
|
4.999.999
USD
|
|
2023-04-06 |
2023-04-06 |
V
Verkauf
|
Huang Jane
President, CMO
Führungsperson
|
13.280
-35.4%
6,12
81.274
USD
|
13.280
-35.4%
|
6,12
|
81.274
USD
|
|
2022-12-21 |
2022-12-20 |
K
Kauf
|
Vaddi Krishna
CEO
Geschäftsführender Verwaltungsratsmitglied
|
19.188
+18.9%
5,13
98.446
USD
|
19.188
+18.9%
|
5,13
|
98.446
USD
|
|
2022-12-12 |
2022-12-08 |
GK
Geplanter Kauf
|
Chardonnet Laurent
Chief Financial Officer
Führungsperson
|
10.000
+38.7%
4,76
47.600
USD
|
10.000
+38.7%
|
4,76
|
47.600
USD
|
|
2022-06-01 |
2022-06-01 |
K
Kauf
|
Chardonnet Laurent
Chief Financial Officer
Führungsperson
|
10.000
+69.0%
4,23
42.300
USD
|
10.000
+69.0%
|
4,23
|
42.300
USD
|
|
2021-12-17 |
2021-12-15 |
GV
Geplanter Verkauf
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Führungsperson
|
28.751
-98.5%
13,00
373.763
USD
|
28.751
-98.5%
|
13,00
|
373.763
USD
|
|
2021-12-15 |
2021-12-14 |
K
Kauf
|
Combs Andrew
EVP, Head of Chemistry
Führungsperson
|
4.000
+1.5%
11,60
46.400
USD
|
4.000
+1.5%
|
11,60
|
46.400
USD
|
|
2021-12-15 |
2021-12-13 |
K
Kauf
|
Combs Andrew
EVP, Head of Chemistry
Führungsperson
|
4.000
+1.5%
12,12
48.480
USD
|
4.000
+1.5%
|
12,12
|
48.480
USD
|
|
2021-11-18 |
2021-11-16 |
GV
Geplanter Verkauf
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Führungsperson
|
400
-47.4%
16,43
6.570
USD
|
400
-47.4%
|
16,43
|
6.570
USD
|
|
2021-11-18 |
2021-11-16 |
GV
Geplanter Verkauf
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Führungsperson
|
28.351
-97.1%
15,87
449.962
USD
|
28.351
-97.1%
|
15,87
|
449.962
USD
|
|
2021-10-06 |
2021-10-05 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
1.289
-100.0%
32,06
41.330
USD
|
1.289
-100.0%
|
32,06
|
41.330
USD
|
|
2021-10-06 |
2021-10-05 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
7.803
-85.8%
31,30
244.257
USD
|
7.803
-85.8%
|
31,30
|
244.257
USD
|
|
2021-10-06 |
2021-10-05 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
5.908
-39.4%
30,26
178.762
USD
|
5.908
-39.4%
|
30,26
|
178.762
USD
|
|
2021-06-09 |
2021-06-07 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
12.700
-100.0%
32,73
415.665
USD
|
12.700
-100.0%
|
32,73
|
415.665
USD
|
|
2021-06-09 |
2021-06-07 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
900
-6.6%
31,62
28.462
USD
|
900
-6.6%
|
31,62
|
28.462
USD
|
|
2021-06-09 |
2021-06-07 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
1.400
-9.3%
30,35
42.496
USD
|
1.400
-9.3%
|
30,35
|
42.496
USD
|
|
2021-05-27 |
2021-05-25 |
GV
Geplanter Verkauf
|
Piper Brian
Chief Financial Officer
Führungsperson
|
399
-100.0%
36,09
14.401
USD
|
399
-100.0%
|
36,09
|
14.401
USD
|
|
2021-05-27 |
2021-05-25 |
GV
Geplanter Verkauf
|
Piper Brian
Chief Financial Officer
Führungsperson
|
1.736
-81.3%
35,45
61.536
USD
|
1.736
-81.3%
|
35,45
|
61.536
USD
|
|
2021-05-27 |
2021-05-25 |
GV
Geplanter Verkauf
|
Piper Brian
Chief Financial Officer
Führungsperson
|
3.088
-59.1%
34,11
105.338
USD
|
3.088
-59.1%
|
34,11
|
105.338
USD
|
|
2021-05-27 |
2021-05-25 |
GV
Geplanter Verkauf
|
Piper Brian
Chief Financial Officer
Führungsperson
|
3.110
-37.3%
33,53
104.263
USD
|
3.110
-37.3%
|
33,53
|
104.263
USD
|
|
2021-05-11 |
2021-05-07 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
200
-0.1%
41,85
8.370
USD
|
200
-0.1%
|
41,85
|
8.370
USD
|
|
2021-05-11 |
2021-05-07 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
5.836
-3.3%
41,14
240.090
USD
|
5.836
-3.3%
|
41,14
|
240.090
USD
|
|
2021-05-11 |
2021-05-07 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
3.964
-2.2%
40,30
159.732
USD
|
3.964
-2.2%
|
40,30
|
159.732
USD
|
|
2021-05-10 |
2021-05-05 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
1.109
-100.0%
41,07
45.545
USD
|
1.109
-100.0%
|
41,07
|
45.545
USD
|
|
2021-05-10 |
2021-05-05 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
10.476
-90.4%
40,30
422.148
USD
|
10.476
-90.4%
|
40,30
|
422.148
USD
|
|
2021-05-10 |
2021-05-05 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
3.415
-22.8%
39,36
134.399
USD
|
3.415
-22.8%
|
39,36
|
134.399
USD
|
|
2021-04-30 |
2021-04-29 |
GV
Geplanter Verkauf
|
Pierce Christopher
EVP and Chief of Business Oper
Führungsperson
|
3.295
-46.8%
40,29
132.765
USD
|
3.295
-46.8%
|
40,29
|
132.765
USD
|
|
2021-04-30 |
2021-04-29 |
GV
Geplanter Verkauf
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Führungsperson
|
3.223
-87.9%
40,29
129.853
USD
|
3.223
-87.9%
|
40,29
|
129.853
USD
|
|
2021-04-29 |
2021-04-27 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
1.711
-100.0%
36,11
61.791
USD
|
1.711
-100.0%
|
36,11
|
61.791
USD
|
|
2021-04-29 |
2021-04-27 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
15.601
-90.1%
35,68
556.580
USD
|
15.601
-90.1%
|
35,68
|
556.580
USD
|
|
2021-04-29 |
2021-04-27 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
7.688
-30.8%
34,66
266.478
USD
|
7.688
-30.8%
|
34,66
|
266.478
USD
|
|
2021-04-21 |
2021-04-19 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
4.000
-100.0%
31,27
125.077
USD
|
4.000
-100.0%
|
31,27
|
125.077
USD
|
|
2021-04-21 |
2021-04-19 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
21.000
-84.0%
30,82
647.273
USD
|
21.000
-84.0%
|
30,82
|
647.273
USD
|
|
2021-04-15 |
2021-04-08 |
GV
Geplanter Verkauf
|
Pierce Christopher
EVP and Chief of Business Oper
Führungsperson
|
200
-5.1%
40,00
8.000
USD
|
200
-5.1%
|
40,00
|
8.000
USD
|
|
2021-04-15 |
2021-04-08 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
1.669
-1.0%
39,57
66.040
USD
|
1.669
-1.0%
|
39,57
|
66.040
USD
|
|
2021-04-15 |
2021-04-08 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
669
-0.4%
38,97
26.073
USD
|
669
-0.4%
|
38,97
|
26.073
USD
|
|
2021-04-15 |
2021-04-08 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
875
-0.5%
37,72
33.003
USD
|
875
-0.5%
|
37,72
|
33.003
USD
|
|
2021-04-15 |
2021-04-08 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
1.417
-0.8%
36,97
52.387
USD
|
1.417
-0.8%
|
36,97
|
52.387
USD
|
|
2021-04-09 |
2021-04-07 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
200
-0.1%
40,30
8.060
USD
|
200
-0.1%
|
40,30
|
8.060
USD
|
|
2021-04-09 |
2021-04-07 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
6.881
-3.8%
39,63
272.679
USD
|
6.881
-3.8%
|
39,63
|
272.679
USD
|
|
2021-04-09 |
2021-04-07 |
GV
Geplanter Verkauf
|
Scherle Peggy
Chief Scientific Officer
Führungsperson
|
8.289
-4.4%
39,02
323.405
USD
|
8.289
-4.4%
|
39,02
|
323.405
USD
|
|
2021-04-09 |
2021-04-07 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
7.083
-100.0%
39,69
281.116
USD
|
7.083
-100.0%
|
39,69
|
281.116
USD
|
|
2021-04-09 |
2021-04-07 |
GV
Geplanter Verkauf
|
Mauro David J
Chief Medical Officer
Führungsperson
|
8.300
-54.0%
39,03
323.908
USD
|
8.300
-54.0%
|
39,03
|
323.908
USD
|
|
2020-09-29 |
2020-09-29 |
K
Kauf
|
Combs Andrew
EVP, Head of Chemistry
Führungsperson
|
1.000
+0.4%
19,00
19.000
USD
|
1.000
+0.4%
|
19,00
|
19.000
USD
|
|
2020-09-29 |
2020-09-29 |
K
Kauf
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Führungsperson
|
444
+inf%
19,00
8.436
USD
|
444
+inf%
|
19,00
|
8.436
USD
|
|
2020-09-29 |
2020-09-29 |
K
Kauf
|
Dier Mardi
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
+inf%
19,00
190.000
USD
|
10.000
+inf%
|
19,00
|
190.000
USD
|
|
2020-09-29 |
2020-09-29 |
K
Kauf
|
Pierce Christopher
EVP and Chief of Business Oper
Führungsperson
|
3.750
+inf%
19,00
71.250
USD
|
3.750
+inf%
|
19,00
|
71.250
USD
|
|
2020-09-29 |
2020-09-25 |
K
Kauf
|
ORBIMED ADVISORS LLC
Nicht geschäftsführender Verwaltungsratsmitglied
Large shareholder
|
710.500
+343.4%
19,00
13.499.500
USD
|
710.500
+343.4%
|
19,00
|
13.499.500
USD
|
|
2020-09-29 |
2020-09-25 |
K
Kauf
|
ORBIMED ADVISORS LLC
Nicht geschäftsführender Verwaltungsratsmitglied
Large shareholder
|
526.300
+inf%
19,00
9.999.700
USD
|
526.300
+inf%
|
19,00
|
9.999.700
USD
|
|